Fundación Gecp

This study is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps control stage III lung cancer better. About 100 patients will first receive the combination treatment to try to shrink tumors. Doctors will then decide if surgery is possible, …

This study is testing whether a drug called tarlatamab can help keep limited-stage small cell lung cancer from getting worse after initial treatment. It will enroll 37 patients who have already completed a specific type of chemo-radiotherapy but were not eligible for a more inten…

This study is testing if using a blood test (ctDNA) to guide treatment decisions helps people with advanced lung cancer live longer. All 63 participants will first receive an immunotherapy drug (cemiplimab). After two cycles, doctors will check the blood test results and the pati…

This study aims to understand how the immune system responds to standard treatments for advanced lung cancer. Researchers will analyze blood and tumor samples from 50 patients who have already received chemotherapy, radiation, and immunotherapy as part of their regular care. The …

This study is looking back at the medical records of 150 people with a specific stage of lung cancer. The goal is to see if how much the tumor shrinks after chemotherapy (given before surgery) can predict how long patients live or stay cancer-free. Researchers are not testing a n…